Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined disease
Last Closing Price
December 13, 2017
Goldman Sachs, Morgan Stanley, Cowen
To view the prospectus for Blueprint Medicines, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253